Crescita Therapeutics (CTX) Q2 2025 earnings summary

Executive summary

• Q2-25 revenue was $6.2M, up 52% year-over-year, driven by new manufacturing contracts and Skincare segment growth.

• Net income reached $0.8M, reversing a net loss of $0.9M in Q2-24.

• Adjusted EBITDA improved to $0.96M from negative $0.69M, reflecting operational gains and a one-time termination payment.

• Gross margin rose to 61.4% from 54.7% in Q2-24.

• A mutual termination agreement with Croma contributed approximately $900K to revenue and cash.

Financial highlights

• Gross profit increased to $3.8M from $2.2M, with gross margin at 61.4%.

• Operating expenses remained stable at $3.2M.

• Cash at quarter-end was $8.2M, with working capital of $9.7M.

• Basic EPS was $0.04, compared to $(0.05) in Q2-24.

• Adjusted EBITDA was $0.96M, up from negative $0.69M.

Outlook and guidance

• Sufficient cash and credit facility available to fund operations and growth initiatives.

• Management is optimistic about growth prospects and is exploring strategic opportunities, including new partnerships for Pliaglis in Europe.

• Focus remains on executing the Four-Pillar Growth Strategy: organic growth, acquisitions, out-licensing, and contract manufacturing.

• Ability to raise additional financing may be impacted by external market conditions.